Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Swiss Med Wkly ; 148: w14593, 2018.
Article in English | MEDLINE | ID: mdl-29451946

ABSTRACT

AIMS OF THE STUDY: Cystic fibrosis is the most common genetic disorder in Caucasians. The combination of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector lumacaftor / potentiator ivacaftor (LUM/IVA) has been shown to increase forced expiratory volume in 1 second (FEV1) moderately, but predominantly reduce acute exacerbation rate (AER) in Phe508del homozygous cystic fibrosis patients; however, patients with FEV1 <40% predicted were excluded from studies. We used LUM/IVA on a "compassionate use" basis in cystic fibrosis patients with end-stage pulmonary disease. Our aim was to evaluate if this patient cohort tolerates LUM/IVA treatment and if there is clinical stabilisation. Lung transplantation (LTX) is the ultimate treatment option for these patients despite maximal therapy. If LTX candidates stabilise clinically, conditions for LTX, when it is indicated, improve. This is particularly important in countries such as Switzerland with a low organ donation rate and long waiting times for suitable donor organs. METHODS: We included all patients from the Adult Cystic Fibrosis Centre at the University Hospital Zurich with Phe508del homozygous genotype and a predicted FEV1 <40% or being evaluated or already listed for LTX. Clinical outcome data comprised AER, 6-minute walking distance (6-MWD), FEV1, forced vital capacity (FVC), mid-expiratory flow (MEF 25-75%), sweat chloride, body mass index (BMI) and quality of life. Respiratory-related adverse events (RAEs) were recorded. LUM/IVA treatment was initiated at a low dose and the dose increased stepwise. RESULTS: Twenty patients were on trial with LUM/IVA; at the cut-off date, 6-month follow-up was complete for 10 patients. RAEs were severe and occurred early. The dropout rate due to RAE or lack of clinical success was 20%. Median AER decreased from 2.5 in the 6 months pre-treatment to 1 during the observation period. FEV1 increased from 32 to 34.5% predicted, p = 0.292. The 6-MWD increased by a median 33 m (p = 0.6086). Sweat chloride decreased significantly by a median of 25 mmol/l (p = 0.0003). Median BMI increased from 19 to 19.9 kg/m2 (p = 0.1488). At the cut-off, three previously listed patients were paused on the transplant waiting list. CONCLUSION: Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease tolerated LUM/IVA, although RAEs occurred early and were severe. This positive finding was probably due to the stepwise dose increases. There was clinical benefit mainly from reduction in AER and stabilisation of lung function. We propose that all suitable Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease should have a trial of LUM/IVA treatment in experienced centres.


Subject(s)
Aminophenols/adverse effects , Aminophenols/therapeutic use , Aminopyridines/adverse effects , Aminopyridines/therapeutic use , Benzodioxoles/adverse effects , Benzodioxoles/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/drug therapy , Quinolones/adverse effects , Quinolones/therapeutic use , Cystic Fibrosis/genetics , Cystic Fibrosis/mortality , Drug Combinations , Genotype , Homozygote , Humans , Lung Transplantation , Male , Mutation/genetics , Prospective Studies , Severity of Illness Index , Switzerland
3.
Eur Heart J ; 33(13): 1589-97, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22240497

ABSTRACT

AIMS: Extracts from pine tree bark containing a variety of flavonoids have been used in traditional medicine. Pycnogenol is a proprietary bark extract of the French maritime pine tree (Pinus pinaster ssp. atlantica) that exerts antioxidative, anti-inflammatory, and anti-platelet effects. However, the effects of Pycnogenol on endothelial dysfunction, a precursor of atherosclerosis and cardiovascular events, remain still elusive. METHODS AND RESULTS: Twenty-three patients with coronary artery disease (CAD) completed this randomized, double-blind, placebo-controlled cross-over study. Patients received Pycnogenol (200 mg/day) for 8 weeks followed by placebo or vice versa on top of standard cardiovascular therapy. Between the two treatment periods, a 2-week washout period was scheduled. At baseline and after each treatment period, endothelial function, non-invasively assessed by flow-mediated dilatation (FMD) of the brachial artery using high-resolution ultrasound, biomarkers of oxidative stress and inflammation, platelet adhesion, and 24 h blood pressure monitoring were evaluated. In CAD patients, Pycnogenol treatment was associated with an improvement of FMD from 5.3 ± 2.6 to 7.0 ± 3.1 (P < 0.0001), while no change was observed with placebo (5.4 ± 2.4 to 4.7 ± 2.0; P = 0.051). This difference between study groups was significant [estimated treatment effect 2.75; 95% confidence interval (CI): 1.75, 3.75, P < 0.0001]. 15-F(2t)-Isoprostane, an index of oxidative stress, significantly decreased from 0.71 ± 0.09 to 0.66 ± 0.13 after Pycnogenol treatment, while no change was observed in the placebo group (mean difference 0.06 pg/mL with an associated 95% CI (0.01, 0.11), P = 0.012]. Inflammation markers, platelet adhesion, and blood pressure did not change after treatment with Pycnogenol or placebo. CONCLUSION: This study provides the first evidence that the antioxidant Pycnogenol improves endothelial function in patients with CAD by reducing oxidative stress.


Subject(s)
Antioxidants/administration & dosage , Coronary Artery Disease/drug therapy , Endothelium, Vascular/drug effects , Flavonoids/administration & dosage , Vasodilation/drug effects , Adult , Aged , Anti-Inflammatory Agents/administration & dosage , Antihypertensive Agents/administration & dosage , Arginine/analogs & derivatives , Arginine/metabolism , Biomarkers/metabolism , Blood Platelets/drug effects , Blood Pressure/drug effects , C-Reactive Protein/metabolism , Coronary Artery Disease/physiopathology , Cross-Over Studies , Double-Blind Method , Endothelin-1/drug effects , Female , Humans , Male , Middle Aged , Oxidative Stress/drug effects , Plant Extracts , Prospective Studies , Shear Strength , Treatment Outcome , Vasodilator Agents/administration & dosage
4.
Eur Heart J ; 33(17): 2172-80, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22173910

ABSTRACT

AIMS: Flavanol-rich chocolate (FRC) is beneficial for vascular and platelet function by increasing nitric oxide bioavailability and decreasing oxidative stress. Congestive heart failure (CHF) is characterized by impaired endothelial and increased platelet reactivity. As statins are ineffective in CHF, alternative therapies are a clinical need. We therefore investigated whether FRC might improve cardiovascular function in patients with CHF. METHODS AND RESULTS: Twenty patients with CHF were enrolled in a double-blind, randomized placebo-controlled trial, comparing the effect of commercially available FRC with cocoa-liquor-free control chocolate (CC) on endothelial and platelet function in the short term (2 h after ingestion of a chocolate bar) and long term (4 weeks, two chocolate bars/day). Endothelial function was assessed non-invasively by flow-mediated vasodilatation of the brachial artery. Flow-mediated vasodilatation significantly improved from 4.98 ± 1.95 to 5.98 ± 2.32% (P = 0.045 and 0.02 for between-group changes) 2h after intake of FRC to 6.86 ± 1.76% after 4 weeks of daily intake (P = 0.03 and 0.004 for between groups). No effect on endothelial-independent vasodilatation was observed. Platelet adhesion significantly decreased from 3.9 ± 1.3 to 3.0 ± 1.3% (P = 0.03 and 0.05 for between groups) 2 h after FRC, an effect that was not sustained at 2 and 4 weeks. Cocoa-liquor-free CC had no effect, either on endothelial function or on platelet function. Blood pressure and heart rate did not change in either group. CONCLUSION: Flavanol-rich chocolate acutely improves vascular function in patients with CHF. A sustained effect was seen after daily consumption over a 4-week period, even after 12 h abstinence. These beneficial effects were paralleled by an inhibition of platelet function in the presence of FRC only.


Subject(s)
Cacao/physiology , Candy , Flavonols/pharmacology , Heart Failure/physiopathology , Ankle Brachial Index , Baroreflex/drug effects , Biomarkers/metabolism , Blood Pressure/drug effects , Double-Blind Method , Endothelium, Vascular/physiology , Female , Flavonols/blood , Heart Rate/drug effects , Humans , Male , Middle Aged , Oxidative Stress/drug effects , Platelet Adhesiveness/drug effects , Polyphenols/blood , Vasodilation/drug effects
5.
Circulation ; 122(18): 1789-96, 2010 Nov 02.
Article in English | MEDLINE | ID: mdl-20956208

ABSTRACT

BACKGROUND: Because traditional nonsteroidal antiinflammatory drugs are associated with increased risk for acute cardiovascular events, current guidelines recommend acetaminophen as the first-line analgesic of choice on the assumption of its greater cardiovascular safety. Data from randomized clinical trials prospectively addressing cardiovascular safety of acetaminophen, however, are still lacking, particularly in patients at increased cardiovascular risk. Hence, the aim of this study was to evaluate the safety of acetaminophen in patients with coronary artery disease. METHODS AND RESULTS: The 33 patients with coronary artery disease included in this randomized, double-blind, placebo-controlled, crossover study received acetaminophen (1 g TID) on top of standard cardiovascular therapy for 2 weeks. Ambulatory blood pressure, heart rate, endothelium-dependent and -independent vasodilatation, platelet function, endothelial progenitor cells, markers of the renin-angiotensin system, inflammation, and oxidative stress were determined at baseline and after each treatment period. Treatment with acetaminophen resulted in a significant increase in mean systolic (from 122.4±11.9 to 125.3±12.0 mm Hg P=0.02 versus placebo) and diastolic (from 73.2±6.9 to 75.4±7.9 mm Hg P=0.02 versus placebo) ambulatory blood pressures. On the other hand, heart rate, endothelial function, early endothelial progenitor cells, and platelet function did not change. CONCLUSIONS: This study demonstrates for the first time that acetaminophen induces a significant increase in ambulatory blood pressure in patients with coronary artery disease. Thus, the use of acetaminophen should be evaluated as rigorously as traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors, particularly in patients at increased cardiovascular risk. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00534651.


Subject(s)
Acetaminophen/adverse effects , Acetaminophen/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Blood Pressure/drug effects , Coronary Artery Disease/physiopathology , Hypertension/chemically induced , Aged , Blood Pressure/physiology , Circadian Rhythm/drug effects , Circadian Rhythm/physiology , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiopathology , Female , Heart Rate/drug effects , Heart Rate/physiology , Humans , Hypertension/epidemiology , Hypertension/physiopathology , Male , Middle Aged , Platelet Adhesiveness/drug effects , Platelet Adhesiveness/physiology , Prospective Studies , Risk Factors , Vasodilation/drug effects , Vasodilation/physiology
6.
Int J Cardiol ; 129(1): 141-3, 2008 Sep 16.
Article in English | MEDLINE | ID: mdl-17720264

ABSTRACT

Sleep apnoea syndrome is frequent in patients with heart failure and associated with a worse prognosis. We evaluated a new device (Auricall) for non-invasive, continuous recording of oxygen saturation (SpO(2)) and heart rate (HR) in patients with heart failure. We studied 20 patients (mean age 48.43+/-14.4 years, NYHA class II-III). All patients were requested to carry the device for at least 36 h and to write a diary during the recording time. Satisfactory recording of SpO(2) and HR was possible to obtain in 18 of 20 patients. Indeed 9 out of 18 patients showed significant periodic changes in SpO(2) during sleep. Therefore, Auricall is a useful tool to non-invasively monitor SpO(2) and HR in patients with heart failure and to detect breathing disorders in these patients.


Subject(s)
Heart Failure/metabolism , Heart Rate/physiology , Monitoring, Ambulatory/instrumentation , Monitoring, Ambulatory/trends , Oxygen Consumption/physiology , Adult , Female , Heart Failure/diagnosis , Humans , Male , Middle Aged , Monitoring, Ambulatory/methods , Oximetry/instrumentation , Oximetry/methods , Sleep Apnea Syndromes/diagnosis , Sleep Apnea Syndromes/metabolism
7.
Arthritis Rheum ; 48(10): 2788-95, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14558084

ABSTRACT

OBJECTIVE: To characterize the expression pattern and role of galectin 3 and galectin 3 binding protein (G3BP) in rheumatoid arthritis (RA), in comparison with galectin 1, and to explore whether soluble galectin 3 and G3BP, investigated in serum, synovial fluid, or cell culture supernatant, are associated with disease. METHODS: Synovial tissues from patients with RA or osteoarthritis (OA), as well as from healthy controls, were analyzed for galectins 1 and 3 and G3BP by in situ hybridization and immunohistochemistry. Levels of galectin 3 and G3BP in serum and synovial fluid from patients with RA and OA and controls, as well as in cell culture supernatants, were determined by enzyme-linked immunosorbent assay (ELISA). In vitro, the intracellular expression of galectin 3 in RA and OA synovial fibroblasts after modulation with tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and anti-CD40 monoclonal antibodies was measured by flow cytometry. RESULTS: In RA, galectin 3 messenger RNA and protein stained throughout the synovial membrane, whereas G3BP was particularly expressed at sites of bone destruction. In contrast, the expression of galectin 1 was not uniform in different RA specimens, and was never found at sites of invasion. In OA and normal synovial tissues, only a small number of cells were positive for galectins and/or G3BP. Galectin 3 was elevated in RA sera and synovial fluids, whereas G3BP was increased in RA synovial fluids only. In RA, serum galectin 3 correlated with C-reactive protein levels, whereas G3BP was associated with joint destruction and/or synovial cell activation as measured by the levels of cartilage oligomeric matrix protein. In vitro, RA synovial fibroblasts showed an increased release of galectin 3 into culture medium, as measured by ELISA, but decreased secretion of G3BP. In RA synovial fibroblasts with low basal expression of galectin 3, TNFalpha increased its intracellular level in a dose-dependent manner. In contrast, IL-1beta or anti-CD40 monoclonal antibodies showed no effect. CONCLUSION: Our data indicate that galectin 3 and G3BP are not only involved in inflammation, but also contribute to the activation of synovial fibroblasts. The intracellular accumulation of galectin 3 can be enhanced by TNFalpha. Thus, galectin 3 and G3BP represent novel markers of disease activity in RA.


Subject(s)
Arthritis, Rheumatoid/physiopathology , Carrier Proteins/blood , Carrier Proteins/genetics , Galectin 3/blood , Galectin 3/genetics , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/metabolism , Biomarkers , C-Reactive Protein/metabolism , Cartilage Oligomeric Matrix Protein , Cell Adhesion/immunology , DNA Helicases , Extracellular Matrix Proteins/metabolism , Fibroblasts/cytology , Fibroblasts/physiology , Gene Expression , Glycoproteins/metabolism , Humans , In Vitro Techniques , Interleukin-1/metabolism , Matrilin Proteins , Osteoarthritis/immunology , Osteoarthritis/metabolism , Osteoarthritis/physiopathology , Poly-ADP-Ribose Binding Proteins , RNA Helicases , RNA Recognition Motif Proteins , RNA, Messenger/analysis , Synovial Fluid/metabolism , Synovial Membrane/cytology , Synovial Membrane/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...